Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety

被引：6

作者：

Hida, Toyoaki ^{[1
]}

机构：

[1] Aichi Canc Ctr Hosp, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan

来源：

THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE | 2018年 / 12卷

关键词：

Nivolumab; Non-small cell lung cancer; PD-1; inhibitor; Japanese; LONG-TERM SAFETY; ANTI-PD-1; ANTIBODY; DOCETAXEL; RECURRENT; SURVIVAL;

D O I：

10.1177/1753466618801167

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Programmed cell death (PD)-1 immune checkpoint inhibitors have emerged as promising options for the treatment of multiple cancer types. Nivolumab is a fully human immunoglobulin G4 monoclonal antibody, which inhibits the PD-1 receptor and has been approved in the United States, Europe, and Asia for the treatment of advanced NSCLC. This review focuses on nivolumab's efficacy and safety in the treatment of NSCLC patients in Japan.

引用

页数：4

共 15 条

[1] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[2] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[3]

Bristol Myers Squibb, 2015, NIV PRESCR INF PACK

[4]

Bristol-Myers Squibb, 2015, NIV SUMM PROD CHAR

[5] Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer [J].

Gettinger, Scott N. ;

Horn, Leora ;

Gandhi, Leena ;

Spigel, David R. ;

Antonia, Scott J. ;

Rizvi, Naiyer A. ;

Powderly, John D. ;

Heist, Rebecca S. ;

Carvajal, Richard D. ;

Jackman, David M. ;

Sequist, Lecia V. ;

Smith, David C. ;

Leming, Philip ;

Carbone, David P. ;

Pinder-Schenck, Mary C. ;

Topalian, Suzanne L. ;

Hodi, F. Stephen ;

Sosman, Jeffrey A. ;

Sznol, Mario ;

McDermott, David F. ;

Pardoll, Drew M. ;

Sankar, Vindira ;

Ahlers, Christoph M. ;

Salvati, Mark ;

Wigginton, Jon M. ;

Hellmann, Matthew D. ;

Kollia, Georgia D. ;

Gupta, Ashok K. ;

Brahmer, Julie R. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (18) :2004-U32

[6] Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non-small cell lung cancer [J].

Hida, Toyoaki ;

Nishio, Makoto ;

Nogami, Naoyuki ;

Ohe, Yuichiro ;

Nokihara, Hiroshi ;

Sakai, Hiroshi ;

Satouchi, Miyako ;

Nakagawa, Kazuhiko ;

Takenoyama, Mitsuhiro ;

Isobe, Hiroshi ;

Fujita, Shiro ;

Tanaka, Hiroshi ;

Minato, Koichi ;

Takahashi, Toshiaki ;

Maemondo, Makoto ;

Takeda, Koji ;

Saka, Hideo ;

Goto, Koichi ;

Atagi, Shinji ;

Hirashima, Tomonori ;

Sumiyoshi, Naoki ;

Tamura, Tomohide .

CANCER SCIENCE, 2017, 108 (05) :1000-1006

[7] Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study [J].

Kanda, S. ;

Goto, K. ;

Shiraishi, H. ;

Kubo, E. ;

Tanaka, A. ;

Utsumi, H. ;

Sunami, K. ;

Kitazono, S. ;

Mizugaki, H. ;

Horinouchi, H. ;

Fujiwara, Y. ;

Nokihara, H. ;

Yamamoto, N. ;

Hozumi, H. ;

Tamura, T. .

ANNALS OF ONCOLOGY, 2016, 27 (12) :2242-2250

[8] Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer [J].

Kato, Terufumi ;

Masuda, Noriyuki ;

Nakanishi, Yoichi ;

Takahashi, Masashi ;

Hida, Toyoaki ;

Sakai, Hiroshi ;

Atagi, Shinji ;

Fujita, Shiro ;

Tanaka, Hiroshi ;

Takeda, Koji ;

Satouchi, Miyako ;

Namba, Yoshinobu ;

Tamura, Tomohide .

LUNG CANCER, 2017, 104 :111-118

[9] Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab [J].

McDermott, David F. ;

Drake, Charles G. ;

Sznol, Mario ;

Choueiri, Toni K. ;

Powderly, John D. ;

Smith, David C. ;

Brahmer, Julie R. ;

Carvajal, Richard D. ;

Hammers, Hans J. ;

Puzanov, Igor ;

Hodi, F. Stephen ;

Kluger, Harriet M. ;

Topalian, Suzanne L. ;

Pardoll, Drew M. ;

Wigginton, Jon M. ;

Kollia, Georgia D. ;

Gupta, Ashok ;

McDonald, Dan ;

Sankar, Vindira ;

Sosman, Jeffrey A. ;

Atkins, Michael B. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (18) :2013-U42

[10] Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer [J].

Nishio, Makoto ;

Hida, Toyoaki ;

Atagi, Shinji ;

Sakai, Hiroshi ;

Nakagawa, Kazuhiko ;

Takahashi, Toshiaki ;

Nogami, Naoyuki ;

Saka, Hideo ;

Takenoyama, Mitsuhiro ;

Maemondo, Makoto ;

Ohe, Yuichiro ;

Nokihara, Hiroshi ;

Hirashima, Tomonori ;

Tanaka, Hiroshi ;

Fujita, Shiro ;

Takeda, Koji ;

Goto, Koichi ;

Satouchi, Miyako ;

Isobe, Hiroshi ;

Minato, Koichi ;

Sumiyoshi, Naoki ;

Tamura, Tomohide .

ESMO OPEN, 2017, 2

← 1 2 →